Stock 1477 OCUMENSION THERAPEUTICS
Add to a list
To use this feature you must be a member
Log inSign up

All News Ocumension Therapeutics

Equities

1477

KYG674111011

Market Closed - Hong Kong S.E.
Other stock markets
 04:08:16 2024-04-24 am EDT 		5-day change 1st Jan Change
6.03 HKD +1.17% Intraday chart for Ocumension Therapeutics +2.20% -9.73%
Apr. 15 Ocumension Therapeutics Completes Phase III Trials for Postoperative Inflammation Drug MT
Apr. 15 Ocumension Therapeutics Announces Phase III Clinical Trial of OT-502 in China CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Ocumension Therapeutics Completes Phase III Trials for Postoperative Inflammation Drug
MT
Ocumension Therapeutics Announces Phase III Clinical Trial of OT-502 in China
CI
Ocumension Therapeutics' Eye Drug Completes Clinical Trials, to Apply for NDA Soon
MT
Ocumension Therapeutics Announces Completion of the Phase III Clinical Trial of OT-702 in China
CI
Ocumension Therapeutics’ Loss for 2023 Narrows; Shares Down 4%
MT
OcuMension (01477.HK) Invests Over RMB 123.8 Million in Research, Technology and Self-development Progress in Tandem, Main Product Sales Show Comprehensive Growth
PR
Ocumension Therapeutics Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Ocumension Therapeutics' Phase 2 Trial for Dry Eye Treatment Meets Clinical Endpoints
MT
Ocumension Therapeutics Announces Phase II Clinical Trial of OT-202
CI
Ocumension Therapeutics Cuts Shareholding in Nasdaq-Listed EyePoint Pharmaceuticals
MT
Ocumension Therapeutics Gets Nod to Register Iluvien in Hong Kong
MT
Ocumension Therapeutics Receives Approval for Marketing OT-703 in Hong Kong
CI
Ocumension Therapeutics commences an Equity Buyback for 69,071,128 shares, representing 10% of its issued share capital, under the authorization approved on June 16, 2023.
CI
Ocumension Says Core Product Added to China's National Reimbursement Drug List
MT
China Includes Ocumension's Middle Eye Infection Treatment in Drug Reimbursement List
MT
Eyepoint Pharmaceuticals Insider Sold Shares Worth $19,510,637, According to a Recent SEC Filing
MT
Ocumension Therapeutics Completes Patient Enrollment for Post-Operative Inflammation Drug in China
MT
Ocumension Therapeutics Completes Enrollment in the Phase Iii Clinical Trial of OT-502 in China
CI
Ocumension Therapeutics Plans HK$100 Million Share Buyback
MT
Ocumension Enrolls 213 Patients for Phase II Trial of Eye Medication in China
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 1477 Stock
  4. News Ocumension Therapeutics